Physician profile
Angel Herrera
NPI 1316986680
$12,255.45
in general payments reported to CMS, 2019-2025
54 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 90% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,006 · 2020: $1,204 · 2021: $1,678 · 2022: $2,017 · 2023: $2,425 · 2024: $1,779 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,346 · Education: $4.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,345.98 |
| Education | $4.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,356.81 | 2019-2025 | Evenity, Repatha, Repatha |
| Novo Nordisk INC | $1,350.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,164.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $838.32 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $754.87 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $613.93 | 2019-2025 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Lilly USA, LLC | $569.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $492.89 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $475.82 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $383.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Kowa Pharmaceuticals America, INC. | $359.81 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Janssen Pharmaceuticals, INC | $316.93 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $299.86 | 2021-2023 | |
| Amarin Pharma, INC. | $279.28 | 2019-2022 | |
| Boston Scientific Corporation | $275.41 | 2023-2024 | Watchman Flx |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.